LSKL is a potent and peptide-based inhibitor of Thrombospondin TSP-1 with the potential to be used for treating hypertrophic scar. LSKL peptide was able to inhibit the overexpression of extracellular matrix and contractile ability of HTS (Hypertrophic scar) fibroblasts. In vivo, LSKL could attenuate the thickness of HTS, distortion of collagen alignment and fibrogenesis. Further, LSKL peptide not only remarkably attenuated cell proliferation and migration, but also induced cell apoptosis of HTS fibroblasts. In addition, LSKL peptide significantly suppressed the phosphorylation of PI3K, AKT, and mTOR, while not affecting the phosphorylation of Smad2/3 and MEK/ERK. LSKL might be a promising anti-fibrosis agent to HTS through modulating the PI3K/AKT/mTOR signaling pathway.

纯度：≥98%

CAS：283609-79-0